|
|
||||||||

* Center for Neurologic Diseases, Brigham and Womens Hopsital and Harvard Medical School, Boston, MA 02120; and
National Centre for Cell Science, Ganeshkhind, Pune, India
Inflammation appears to be a necessity for both metastasis and elimination of tumor cells. IL-17, a proinflammatory cytokine produced by Th17 cells, contributes to both the processes by playing a dual role in the antitumor immunity. On one hand, IL-17 promotes an antitumor cytotoxic T cell response leading to tumor regression. On the other hand, by facilitating angiogenesis and egress of tumor cells from the primary focus, IL-17 promotes tumor growth. Thus, the therapeutic application that uses IL-17 needs to be refined by minimizing its protumor functions.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 The work was supported by the Department of Biotechnology, Government of India.
2 Address correspondence and reprint requests to Dr. Bhaskar Saha, Scientist-F, National Centre for Cell Science, Ganeshkhind, Pune 411007, India. E-mail address: sahab{at}nccs.res.in
3 Abbreviations used in this paper: Treg, regulatory T cell; DC, dendritic cell; EAE, experimental autoimmune encephalomyelitis; ROR, retinoid orphan receptor; VEGF, vascular endothelial growth factor.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |